How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,046 results for

Procainamide

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide. The biguanides: phenformin and buformin (but excluding metformin). Drugs that are substrates of the renal transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion protein 2 (MATE1) and multidrug and toxin extrusion protein 2 (MATE2) and have a narrow therapeutic index (for example, the antiarrhythmic agents: dofetilide, procainamide and pilsicainide). Anticipated to be unable to consume daily study

2016 Clinical Trials

182. Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

., diltiazem and verapamil) Class I anti-arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin) Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some macrolide antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, antiretroviral drugs (e.g., ritonavir, nelfinavir), and systemic azole antifungal agents (e.g., ketoconazole, itraconazole), and nefazodone Inducers of cytochrome P450 3A4 (CYP3A4) including St. John's wort, rifampicin, barbiturates, and phenytoin. Treatments

2016 Clinical Trials

183. Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

prophylaxis current treatment or treatment within the past 12 weeks with HDAC inhibitors (eg valproate) taking medication that may increase the dose-dependent side effects myelosuppression or QTc interval prolongation. These include, but are not limited to: Class Ia antiarrhythmic agents such as quinidine, procainamide, disopyramide Class III antiarrhythmic drugs such as amiodarone, sotalol, ibutilide Class Ic antiarrhythmics such as flecainide, propafenone penicillamine opioids such as methadone

2016 Clinical Trials

184. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. (PubMed)

is part of a larger class of ventricular dysrhythmias defined by a rate of at least 120 beats/min with QRS > 120 ms without regularly occurring P:QRS association. Little controversy exists for the treatment of hemodynamically unstable VT. The medical management of hemodynamically stable monomorphic VT is surrounded by controversy. Direct current cardioversion is most efficacious. Guidelines for the treatment of stable VT from the American Heart Association provide a IIa recommendation for procainamide (...) , compared with a IIb recommendation for both amiodarone and sotalol. Studies evaluating procainamide, lidocaine, amiodarone, and sotalol suffer from poor design, difference in inclusion and exclusion criteria, small sample size, and outcome determination. Procainamide demonstrates the greatest efficacy. If procainamide is selected, a maximum dose of 10 mg/kg at 50-100 mg/min intravenous (IV) over 10-20 min should be provided with monitoring of blood pressure and electrocardiogram. Monomorphic VT

2016 Journal of Emergency Medicine

185. Treatment of cocaine cardiovascular toxicity: a systematic review. (PubMed)

in tachycardia and hypertension and risk of extrapyramidal adverse effects. Other agents: There was only one high level study of morphine, which reversed cocaine-induced coronary vasoconstriction but increased heart rate. Other agents reviewed included lidocaine, sodium bicarbonate, amiodarone, procainamide, propofol, intravenous lipid emulsion, propofol, and ketamine.High-quality evidence for pharmacological treatment of cocaine cardiovascular toxicity is limited but can guide acute management of associated

2016 Clinical toxicology (Philadelphia, Pa.)

186. Cardiac Abnormalities in First-Degree Relatives of Unexplained Cardiac Arrest Victims: A Report From the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry. (PubMed)

UCA, 212 sudden unexplained death victims' relatives; mean age, 44±17 years) underwent extensive cardiac workup, including ECG, signal averaged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testing with epinephrine or procainamide. Genetic testing was performed when a mutation was identified in the UCA survivor or when the diagnostic workup revealed a phenotype suggestive of a specific inherited arrhythmia syndrome. The diagnostic strength was classified

Full Text available with Trip Pro

2016 Circulation. Arrhythmia and electrophysiology

187. Novel epigenetic-based therapies useful in cardiovascular medicine (PubMed)

inhibit DNA methyltransferase directly or by reducing its gene expression (e.g., hydralazine and procainamide) are currently under investigation. The anti-proliferative and anti-inflammatory properties of histone deacetylase inhibitors and their cardio-protective effects have been confirmed in preclinical studies. Furthermore, the regulation of the expression of microRNA targets through pharmacological tools is still under development. Indeed, large controlled trials are required to establish whether

Full Text available with Trip Pro

2016 World journal of cardiology

188. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) confirm onset <48 hours IV. Protocol: Step 1 - Rate Control (optional) Indications Symptomatic or Not planning cardioversion and >110 Medications 0.25 mg/kg over 10 min (may repeat at 0.35 mg/kg) 5 mg IV every 15 min as needed (typically up to 3 doses) V. Protocol: Step 2 - Chemical Cardioversion with Procainamide Indications Hemodynamically stable with systolic >100 mmHg No contraindications (see above) Normal and Method 1 g IV over 60 minutes Monitor with frequent s, and hold if systolic <100 mmHg

2018 FP Notebook

189. Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

to ensure the subject?s safety; drugs that are generally accepted to increase the risk of Torsades de Pointes, include (but not limited to): Quinidine, procainamide, disopyramide Amiodarone, ibutilide, dofetilide, sotalol Erythromycin, clarithromycin Chlorpromazine, mesoridazine, thioridazine, pimozide Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine Left ventricular ejection fraction < 50% Uncontrolled

2016 Clinical Trials

190. Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma

, Transient Ischemic Attack, Cerebral Vascular Accident, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris. Anticoagulant therapy with vitamine K antagonists Patients receiving Class 1A (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents Evidence of QTc (corrected QT interval) prolongation on pretreatment ECG (greater than 44ms in males of greater than 450ms in females) Magnesium, potassium and calcium below the lower limit

2016 Clinical Trials

191. Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

≥ 20 ng/ml then only one of the other 3 risk factors is needed) M0 by standard imaging work-up (see chapter 6.1.1.1) Testosterone ≥ 200 ng/dl Adequate renal function: calculated creatinine clearance ≥ 50 mL/min (Appendix D) Magnesium and potassium within normal limits of the institution or corrected to within normal limits prior to the first dose of treatment. Patients with prolonged QT-intervals due to prescribed Class IA (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmic

2016 Clinical Trials

192. The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus

diagnosis of cirrhosis Liver Dysfunction with AST or ALT liver enzymes > 2x upper limit of normal Chronic Kidney Disease with glomerular filtration rate < 45 ml/min/1.73m2 Anemia with hematocrit < 30% TSH > 5 or < 0.4 mIU/L Coagulopathy, INR > 1.3 Use of warfarin or other new oral anticoagulants (dabigatran, rivaroxaban, apixaban) Use of subcutaneous heparin, enoxaparin, dalteparin Use of class 1 or class 3 anti-arrhythmic medications (disopyramide, procainamide, quinidine, mexilitine, flecanide

2016 Clinical Trials

193. ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

] inhibitor (e.g. amiloride [Midamor]; cimetidine [Tagamet]; digoxin [Lanoxin, Digitek, Digox]; dolutegravir [Tivicay]; morphine [Roxanol, Duramorph, Kadian, MS Contin]; procainamide [Pronestyl, Procanbid]; quinidine [Quinidex, Cardioquin, Quin-G, Quinora]; quinine [Qualaquin, Quinamm, Quiphile]; ranitidine [Zantac, Deprizine, Gabitidine]; ranolazine [Ranexa]; triamterene [Dyrenium)] trimethoprim [Proloprim, Trimpex, Primsol]; vancomycin [Vancocin, Vancoled]; or vandetanib [Calpresa]) Participants

2016 Clinical Trials

194. Ottawa Aggressive Atrial Fibrillation Protocol

Administration 4 Ottawa Aggressive Atrial Fibrillation Protocol Ottawa Aggressive Atrial Fibrillation Protocol Aka: Ottawa Aggressive Atrial Fibrillation Protocol , Chemical Cardioversion of Acute Atrial Fibrillation With Procainamide From Related Chapters II. Indications: Cardioversion Acute onset of within prior 48 hours III. Contraindications: Cardioversion Hemodynamically unstable (immediate cardioversion indication) Acute Unclear onset (anticoagulate, no cardioversion and follow-up as below) Cannot (...) confirm onset <48 hours IV. Protocol: Step 1 - Rate Control (optional) Indications Symptomatic or Not planning cardioversion and >110 Medications 0.25 mg/kg over 10 min (may repeat at 0.35 mg/kg) 5 mg IV every 15 min as needed (typically up to 3 doses) V. Protocol: Step 2 - Chemical Cardioversion with Procainamide Indications Hemodynamically stable with systolic >100 mmHg No contraindications (see above) Normal and Method 1 g IV over 60 minutes Monitor with frequent s, and hold if systolic <100 mmHg

2018 FP Notebook

195. Articles of the month (July 2016)

think there are way too many issues with this data and will continue not suggesting antivirals in Bell’s palsy Another knock against amiodarone Ortiz M, Martín A, Arribas F. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. European heart journal. 2016. PMID: This is a multicenter, randomized trial comparing amiodarone (5mg/kg over 20 minutes) to procainamide (10mg/kg over 20 min) in 74 adult (...) patients with hemodynamically stable ventricular tachycardia. The results will be surprising to anyone who has listened to drug reps or the AHA over the last 15 years, but probably not surprising to anyone who has read the prior amiodarone literature. Procainamide was better. The primary outcome of cardiac adverse events (mostly hypotension requiring cardioversion), occurred in 9% of the procainamide group and 41% of the amiodarone group (odds ratio 0.1, 95%CI 0.03-.06, p=0.006). In terms of stopping

2016 First10EM

196. Cardiac Care Revealed On Celebrity Cruise Lines: Afibbers Fear Not

(obviously not all of them)… we have the mentioned monitors with described capabilities, a portable pressure/volume ventilator (used in the US Army in areas of combat). For IV cardiac medications, we have Adenosine, epinephrine 1:1000 and 1:10000, atropine, amiodarone, procainamide, dopamine, dobutamine, furosemide, metoprolol, diltiazem, verapamil, labetalol, digoxin, calcium gluconate and chloride, furosemide lidocaine 2%, magnesium sulfate, norepinephrine, sodium nitroprusside, nitroglycerine

2016 The Skeptical Cardiologist

197. Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis. (PubMed)

database of SVT hospitalizations from 2003 to 2013. High-volume centers (HVC) were defined as those at the upper quartile of admissions. Infants with an ICD-9 code of paroxysmal SVT were included. Antiarrhythmics investigated included amiodarone, atenolol, digoxin, esmolol, flecainide, procainamide, propafenone, propranolol, and sotalol. Frequency of antiarrhythmic use based on center volume was the primary end point. Rate of 30-day SVT readmission was the secondary end point. Analysis of factors

2016 Pediatric Cardiology

198. Wide Complex Tachycardia in a 20 something.

was reluctant to give adenosine. . What would cause this rhythm but have some irregularity on the rhythm strip? Could this be atrial fibrillation? Is adenosine really contraindicated? It is very important that you recognized that the ECG shown CANNOT be Atrial fibrillation with WPW. 1) it is perfectly regular (I even used calipers) 2) When you have atrial fibrillation with WPW, there are multiform QRS complexes. Clinical Course : Procainamide was administered. There was no response. Labs were normal. K

2015 Dr Smith's ECG Blog

199. Is this Type 2 Brugada syndrome/ECG pattern?

dysplasia. Transthoracic echo did not show any evidence of HOCM or right ventricular dysplasia. EF was normal. He had no known family history of sudden cardiac death at a young age. The electrophysiologist was confident that this was not Brugada, that a procainamide challenge test could be done but that this would normally be done only for "unexplained" syncope, not for typical vasovagal syncope. The patient was discharged with no exercise limitations. He left open the possibility of an exercise test

2015 Dr Smith's ECG Blog

200. Administration of medicinal products by non - medical personnel as part of Clinical Nuclear Medicine Procedures

syndrome) may reduce the excretion of procainamide and N- acetylprocainamide resulting in increased plasma level of these drugs. 3) Alteration of gastric pH: The bioavailability of certain drugs may be affected. This can result in either an increase in absorption (e.g. triazolam, midazolam, glipizide) or a decrease in absorption (e.g. ketoconazole, atazanavir, delaviridine, gefitnib).. Contraindications Ranitidine is contraindicated for patients known to have hypersensitivity to any component

2013 British Nuclear Medicine Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>